In Vitro Anti-staphylococcal and Anti-inflammatory Abilities of Lacticaseibacillus rhamnosus from Infant Gut Microbiota as Potential Probiotic Against Infectious Women Mastitis
- PMID: 33649898
- DOI: 10.1007/s12602-021-09755-x
In Vitro Anti-staphylococcal and Anti-inflammatory Abilities of Lacticaseibacillus rhamnosus from Infant Gut Microbiota as Potential Probiotic Against Infectious Women Mastitis
Abstract
Infectious mastitis is the major cause of early weaning, depriving infants of breastfeeding benefits. It is associated with an inflammatory condition of the breast and lowered resistance to infection. Drug administration during lactation often being contra-indicated, it is therefore important to consider safe therapeutic alternatives to antibiotic and anti-inflammatory therapies, such as probiotics. In this study, we investigated in vitro the probiotic potential of thirteen Lacticaseibacillus (formerly Lactobacillus) rhamnosus strains isolated from the gut microbiota of breastfed healthy infants. Strains were assessed for their β-hemolytic activity, their resistance to antibiotics, and their antimicrobial activities against strains of Staphylococcus and Streptococcus, most often involved in women mastitis. Their immunomodulating abilities were also studied using in vitro stimulation of human immune cells. None of the strains exhibited β-hemolytic activity, and all of them were sensitive to ampicillin, penicillin, tetracycline, rifampicin, erythromycin, chloramphenicol, and imipenem but showed resistance to ceftazidime, trimethoprim/sulfamethoxazole, vancomycin, and cefotaxime, reported to be chromosomally encoded and not inducible or transferable. Four L. rhamnosus strains were selected for their large anti-staphylococcal spectrum: L. rhamnosus VR1-5 and L. rhamnosus VR3-1 inhibiting S. aureus, S. epidermis, and S. warneri and L. rhamnosus CB9-2 and L. rhamnosus CB10-5 exerting antagonistic effect against S. aureus and S. epidermis strains. Antimicrobial compounds released in cell-free supernatant showed proteinaceous nature and were thermoresistant. The immune modulatory analysis of the L. rhamnosus strains revealed two strains with significant anti-inflammatory potential, highlighted by strong induction of IL-10 and a weak pro-Th1 cytokine secretion (IL-12 and IFN-γ). L. rhamnosus CB9-2 combined a large anti-staphylococcal activity spectrum and a promising anti-inflammatory profile. This strain, used individually or in a mixture, can be considered as a probiotic candidate for the management of infectious mastitis during lactation.
Keywords: Anti-inflammatory ability; Antibacterial activity; Infant gut microbiota; Infectious mastitis; Lacticaseibacillus rhamnosus; Probiotics.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
References
-
- Wold Health Organization (2000) Mastitis: causes and management. World Health Organization, Geneva, pp 1–45. https://apps.who.int/iris/handle/10665/68543
-
- Giugliani ERJ (2004) Common problems during lactation and their management. J Pediatr (Rio J) 80:8: (5 Suppl.) S147-154. https://doi.org/10.1590/S0021-75572004000700006
-
- Marín M, Arroyo R, Espinosa-Martos I et al (2017) Identification of emerging human mastitis pathogens by MALDI-TOF and assessment of their antibiotic resistance patterns. Front Microbiol 8:1258. https://doi.org/10.3389/fmicb.2017.01258 - DOI - PubMed - PMC
-
- Contreras GA, Rodríguez JM (2011) Mastitis: comparative etiology and epidemiology. J Mammary Gland Biol Neoplasia 16:339–356. https://doi.org/10.1007/s10911-011-9234-0 - DOI - PubMed
-
- Patel SH, Vaidya YH, Patel RJ et al (2017) Culture independent assessment of human milk microbial community in lactational mastitis. Sci Rep 7(1):7804. https://doi.org/10.1038/s41598-017-08451-7 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical